← Eichor
Condition: Amyloid Light Chain Amyloidosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Amyloid Light Chain Amyloidosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

International Cardiac Amyloidosis Registry
Phase N/A · 6 location(s) · Leiden University Medical Center · NCT06894290Teclistamab in Previously Treated AL Amyloidosis
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06935162Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
EARLY_Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07626476Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Phase 1/Phase 2 · 3 location(s) · University of Texas Southwestern Medical Center · NCT05145816Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
Phase 2 · 2 location(s) · Keymed Biosciences Co.Ltd · NCT07039578Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT01408225Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Phase N/A · 4 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06383143A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREK
Phase N/A · 6 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06205953A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an
Phase 2 · 5 location(s) · GlaxoSmithKline · NCT07224672Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With R
NA · 1 location(s) · Beijing Boren Hospital · NCT06983951A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335Daratumumab for Patients With Light Chain Amyloidosis
NA · 1 location(s) · Nanjing University School of Medicine · NCT06376214Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis
Phase 1/Phase 2 · 27 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07266116A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Phase 1 · 1 location(s) · University of Tennessee Graduate School of Medicine · NCT05951816Clinical Study for AL-CM
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04924998A Prospective Cohort Study on Primary Cutaneous Amyloidosis
Phase 4 · 1 location(s) · Army Medical University, China · NCT06998875Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT07085559The Impact of Systemic Light Chain Amyloidosis on Eyes
Phase N/A · 1 location(s) · Zhongshan Ophthalmic Center, Sun Yat-sen University · NCT06803082Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosi
Phase 1 · 9 location(s) · Gracell Biotechnologies (Shanghai) Co., Ltd. · NCT07250269Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07448779Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Phase 2 · 1 location(s) · Polina Stepensky · NCT06971380Hungarian National Systemic Amyloidosis Registry
Phase N/A · 12 location(s) · Semmelweis University · NCT07689331A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethaso
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07388602A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch
Phase 1/Phase 2 · 23 location(s) · AbbVie · NCT06158854Rapid dFLC Response Predict CHR in AL Amyloidosis
Phase N/A · 8 location(s) · Peking University People's Hospital · NCT06627309DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Phase 2 · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT06420167National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT060658523'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Phase 2 · 2 location(s) · Mayo Clinic · NCT05898646
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.